apatinib

01/01/2023 - "Apatinib combined with IMRT is a safe and effective method to improve PFS and DCR and has good anti-tumor activity in patients with uHCC."
01/01/2018 - "The pooled results for the efficacy of apatinib in the treatment of different types of solid tumors revealed that patients treated with apatinib exhibited good disease control. "
03/01/2019 - "The therapeutic efficacy of TACE combined with Apatinib in HCC treatment is higher compared to TACE alone, which may be related to the inhibition of tumor angiogenesis. "
01/01/2018 - "We used objective response rate (ORR) and disease control rate (DCR) to evaluate the efficacy of apatinib for five major types of solid tumors. "
04/01/2015 - "With a favorable side effect profile and improved outcomes, apatinib has demonstrated a substantial potential to augment therapeutic options in a variety of tumor types. "

01/01/2023 - "Apatinib, a highly selective VEGFR2 inhibitor, significantly improved efficacy versus placebo as a third- and later-line treatment for advanced gastric cancer in phase 2 and 3 trials. "
02/01/2018 - "Apatinib has been proven to be effective and safe among patients in the third-line treatment of advanced gastric cancer in phase II and III trials. "
01/01/2022 - "Karelizumab combined with apatinib is effective in the treatment of advanced gastric cancer, with low incidence of adverse reactions and high safety. "
01/01/2022 - "Background: There is strong evidence that apatinib is effective in the treatment of third- or later-line advanced metastatic gastric cancer (mGC). "
02/01/2017 - "Apatinib, a third-line or later treatment for advanced gastric cancer (aGC), was shown to improve overall survival and progression-free survival (PFS) compared with placebo in the phase III trial. "

11/30/2022 - "The combined treatment of transcatheter arterial chemoembolization (TACE) and apatinib had beneficial effects on the survival of patients with advanced hepatocellular carcinoma (HCC), but the efficacy of this regimen is still controversial and needs further investigation. "
01/01/2021 - "Apatinib significantly improved overall survival in patients with pretreated advanced hepatocellular carcinoma compared with placebo, with a manageable safety profile. "
03/04/2022 - "Apatinib combined with TACE is more effective than TACE alone in the treatment of hepatocellular carcinoma, but it has certain adverse reactions."
03/01/2019 - "To explore the therapeutic efficacy and clinical safety of transcatheter arterial chemoembolization (TACE) combined with Apatinib in patients with advanced hepatocellular carcinoma (HCC). "
12/01/2017 - "Apatinib is effective for treatment of advanced hepatocellular carcinoma."

10/01/2019 - "The efficacy of apatinib combination is better than that of monotherapy, and there is no significant difference in toxicity of important organs, which suggests the feasibility of a combination of apatinib in the treatment of non-small cell lung cancer."
01/01/2021 - "This study aimed to explore associations between PDL1 polymorphisms and efficacy of apatinib for patients with previously treated advanced non-small cell lung cancer (NSCLC) in a real-world setting. "
11/20/2017 - "[Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment]."
11/25/2022 - "This study aimed to analyze the predictive value of the neutrophil-to-lymphocyte ratio (NLR) to better clarify which patients with advanced non-small cell lung cancer (NSCLC) would benefit most from apatinib after multiline treatment for drug resistance. "
01/01/2022 - "The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial."

04/24/2018 - "Conclusions: Single-agent apatinib mesylate demonstrated the good short-term efficacy for multi-drug resistant advanced breast cancer in patients who previously underwent multiple line treatment failures. "
01/01/2022 - "This study confirms the reliable efficacy of apatinib monotherapy for advanced breast cancer. "
01/01/2021 - "The aim of this study was to evaluate the safety and efficacy of apatinib in metastatic breast cancer patients pretreated with multiline treatment in a real-world setting. "
01/01/2019 - "The clinical trials have demonstrated the objective efficacy of Apatinib against metastatic breast cancer. "
07/01/2020 - "The evidence shows efficacy of apatinib against breast cancer. "